Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings

Table 4 Number of injections

Number of injections
Time point	6 m pre switch	3 m pre switch	Baseline (switch)	3 m post switch	6 m post switch	9 m post switch	12 m post switch	15 m post switch
Mean number of injections (min- max)	8.6 (0–18)	11 (2–20)	12 (3–21)	2.2 (1–3)	3.6 (1–6)	4.8 (2–7)	5.9 (3–8)	7.3 (3–11)
n	57	57	57	57	57	57	57	57

Time point	18 m post switch	21 m post switch	24 m post switch	27 m post switch	30 m post switch	33 m post switch	36 m post switch
Mean number of injections (min- max)	8.4 (3–13)	9.3 (3–14)	10 (3–15)	11 (3–16)	12 (3–18)	13 (3–20)	14 (3–22)
n	57	57	57	57	57	57	57

Mean (range) number of ranibizumab injections 6 and 3 months before the switch to aflibercept, at the day of the decision to switch and mean (range) number of aflibercept injections every 3 months after the switch up to 36 months follow-up

ISSN: 2056-9920